Literature DB >> 20938346

The role of residual gadolinium in the induction of nephrogenic systemic fibrosis-like skin lesions in rats.

Hubertus Pietsch1, Marian Raschke, Heidrun Ellinger-Ziegelbauer, Gregor Jost, Jakob Walter, Thomas Frenzel, Diana Lenhard, Joachim Hütter, Martin A Sieber.   

Abstract

OBJECTIVE: Nephrogenic systemic fibrosis (NSF) is an acquired, idiopathic disorder. Most of the cases are observed in patients with end stage renal disease (ESRD). The objective of this nonclinical animal study was to test the hypothesis that gadolinium (Gd) deposits play a role in the induction of NSF lesions. In addition, we evaluated whether an acute response to Gd exposure can initiate a process that results in fibrosis of the skin.
MATERIALS AND METHODS: Han-Wistar rats were administered 3 intravenous injections of Gd-DTPA-BMA formulated without Gd-free excess ligand (Gadodiamide without Caldiamide) at a dose of 2.5 mmol/kg of body weight (b.w.) per injection given at 24-hour or 14-, 28-, or 56-day intervals. The occurrence and development of NSF-like fibrosing dermopathy lesions were followed. The Gd concentration was determined by Inductively Coupled Plasma Mass Spectrometry in skin biopsies taken during the study and organ samples taken at the end of the study.In a separate study, after injection of a single intravenous dose of 2.5 mmol/kg b.w. Gd-DTPA-BMA administered to Han-Wistar rats, the expression of cytokines and signaling molecules in serum and skin tissue was determined by quantitative RT-PCR and Luminex technology 6 hours or 14, 28, or 56 days.
RESULTS: The occurrence of NSF-like macroscopic skin lesions differed between the injection groups. Shorter injection intervals resulted in more severe skin reactions. In contrast, the injection interval did not influence the long-term presence and level of accumulation of Gd concentration in tissue. The single injection of Gd-DTPA-BMA was followed by a rapid and transient induction of signaling molecules in the serum (MCP1, MCP3, IL1, IP-10, Osteopontine SCF and Timp1) as well as in the skin (MCP1 and TGFb).
CONCLUSION: The presence of NSF-like fibrosing dermopathy in rats was found to be dependent on the injection interval and not on the amount of Gd in tissue. Our findings suggest the possibility of a more acute intrinsic reaction on administration of Gd-DTPA-BMA that triggers events leading to the development of skin lesions. The finding that single injections of Gd-DTPA-BMA were accompanied by a fast and transient induction of signaling molecules that are known to be involved in several fibrotic events provides additional support for this hypothesis. The study findings, however, do not support the theory that the long-term presence of Gd plays a relevant role in the development of NSF.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20938346     DOI: 10.1097/RLI.0b013e3181efd49a

Source DB:  PubMed          Journal:  Invest Radiol        ISSN: 0020-9996            Impact factor:   6.016


  9 in total

1.  Hyperphosphataemia sensitizes renally impaired rats to the profibrotic effects of gadodiamide.

Authors:  N Fretellier; Jm Idée; P Bruneval; S Guerret; F Daubiné; G Jestin; C Factor; N Poveda; A Dencausse; F Massicot; O Laprévote; C Mandet; N Bouzian; M Port; C Corot
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

2.  Type of MRI contrast, tissue gadolinium, and fibrosis.

Authors:  Catherine Do; Jeffrey L Barnes; Chunyan Tan; Brent Wagner
Journal:  Am J Physiol Renal Physiol       Date:  2014-08-06

3.  Albumin-based nanoparticles as contrast medium for MRI: vascular imaging, tissue and cell interactions, and pharmacokinetics of second-generation nanoparticles.

Authors:  E A Wallnöfer; G C Thurner; C Kremser; H Talasz; M M Stollenwerk; A Helbok; N Klammsteiner; K Albrecht-Schgoer; H Dietrich; W Jaschke; P Debbage
Journal:  Histochem Cell Biol       Date:  2020-10-11       Impact factor: 4.304

Review 4.  Minimizing risk of nephrogenic systemic fibrosis in cardiovascular magnetic resonance.

Authors:  Theresa Reiter; Oliver Ritter; Martin R Prince; Peter Nordbeck; Christoph Wanner; Eike Nagel; Wolfgang Rudolf Bauer
Journal:  J Cardiovasc Magn Reson       Date:  2012-05-20       Impact factor: 5.364

5.  Gadolinium based contrast agents in current practice: Risks of accumulation and toxicity in patients with normal renal function.

Authors:  Anju Ranga; Yatish Agarwal; Kanika J Garg
Journal:  Indian J Radiol Imaging       Date:  2017 Apr-Jun

Review 6.  Gadolinium: pharmacokinetics and toxicity in humans and laboratory animals following contrast agent administration.

Authors:  Julie Davies; Petra Siebenhandl-Wolff; Francois Tranquart; Paul Jones; Paul Evans
Journal:  Arch Toxicol       Date:  2022-01-08       Impact factor: 5.153

Review 7.  Use of Real-Life Safety Data From International Pharmacovigilance Databases to Assess the Importance of Symptoms Associated With Gadolinium Exposure.

Authors:  Imran Shahid; Alvin Joseph; Eric Lancelot
Journal:  Invest Radiol       Date:  2022-04-26       Impact factor: 10.065

Review 8.  Gadolinium Retention: A Research Roadmap from the 2018 NIH/ACR/RSNA Workshop on Gadolinium Chelates.

Authors:  Robert J McDonald; Deborah Levine; Jeffrey Weinreb; Emanuel Kanal; Matthew S Davenport; James H Ellis; Paula M Jacobs; Robert E Lenkinski; Kenneth R Maravilla; Martin R Prince; Howard A Rowley; Michael F Tweedle; Herbert Y Kressel
Journal:  Radiology       Date:  2018-09-11       Impact factor: 11.105

Review 9.  25 Years of Contrast-Enhanced MRI: Developments, Current Challenges and Future Perspectives.

Authors:  Jessica Lohrke; Thomas Frenzel; Jan Endrikat; Filipe Caseiro Alves; Thomas M Grist; Meng Law; Jeong Min Lee; Tim Leiner; Kun-Cheng Li; Konstantin Nikolaou; Martin R Prince; Hans H Schild; Jeffrey C Weinreb; Kohki Yoshikawa; Hubertus Pietsch
Journal:  Adv Ther       Date:  2016-01-25       Impact factor: 3.845

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.